These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8305227)

  • 1. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
    Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
    Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
    Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
    Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
    Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
    Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
    Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
    Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
    Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
    J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.
    Kälkner KM; Janson ET; Nilsson S; Carlsson S; Oberg K; Westlin JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5801s-5804s. PubMed ID: 7493349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.
    Andersson P; Forssell-Aronsson E; Johanson V; Wängberg B; Nilsson O; Fjälling M; Ahlman H
    J Nucl Med; 1996 Dec; 37(12):2002-6. PubMed ID: 8970523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thoracic SPECT using (111 In-DTPA-D-Phe1)-octreotide in bronchial carcinoid syndrome].
    Banzo J; Sebastián A; Prats E; Freile E; García F; Costán J; Razola P; Tomás A; Cegoñino J; Abós MD
    Rev Esp Med Nucl; 1998; 17(1):45-8. PubMed ID: 9609844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
    Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M
    J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.
    Raderer M; Kurtaran A; Leimer M; Angelberger P; Niederle B; Vierhapper H; Vorbeck F; Hejna MH; Scheithauer W; Pidlich J; Virgolini I
    J Clin Oncol; 2000 Mar; 18(6):1331-6. PubMed ID: 10715305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
    Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.